| Literature DB >> 27888708 |
Qiaoshi Xu1, Chong Wang1, Xiaohong Yuan2, Zhien Feng3, Zhengxue Han4.
Abstract
BACKGROUND: The prognostic value of tumor-infiltrating lymphocytes (TILs) in head and neck squamous cell carcinoma (HNSCC) remains controversial. Additionally, there is no standardized approach or cutoff value for evaluating TIL levels. The aim of this study was to establish a feasible method and criterion to assess TIL levels for future clinical practice and research use and to explore the relationship between TIL levels and prognosis. PATIENTS AND METHODS: This retrospective cohort study reviewed the records and pathological sections of 202 patients with HNSCC who were surgically treated at Beijing Stomatological Hospital, Capital Medical University, from January 1998 to January 2011. The predictor variable was the TIL level. The main outcome assessment parameters were disease-free survival (DFS) and disease-specific survival (DSS). RESULT: The T stage (P = .008), smoking history (P = .042), alcohol history (P = .048), need for radiotherapy (P = .012) and microscopic extracapsular spread (ECS) (P = .012) were associated with the TIL level. A cutoff value equal to 70% could be taken as a threshold for TIL assessment, with a TIL level higher than 70% associated with a better prognosis (DFS rate: 51.9%, P = .018; DSS rate: 59.3%, P = .049). The Cox regression model showed that the TIL level was an independent prognostic factor for DFS (hazard ratio (HR): 0.786, 95% CI: 0.618-0.999, P = .049).Entities:
Year: 2016 PMID: 27888708 PMCID: PMC5123038 DOI: 10.1016/j.tranon.2016.10.005
Source DB: PubMed Journal: Transl Oncol ISSN: 1936-5233 Impact factor: 4.243
Figure 1Standardized approach of TIL evaluation for HNSCC patients.
Baseline Demographics of the 202 Patients in this Study
| Variable | No. (%) | Low TILs | Moderate TILs | High TILs | |
|---|---|---|---|---|---|
| No. (%) | No. (%) | No. (%) | |||
| Age, yrs.: mean ± SD | 60.74 ± 13.48 | 0.906 | |||
| ≤60 | 97 (48.0%) | 32 (46.4%) | 36 (48.0%) | 29 (50.0%) | |
| >60 | 105 (52.0%) | 37 (53.6%) | 39 (52.0%) | 29 (50.0%) | |
| Sex | 0.097 | ||||
| Male | 134 (66.3%) | 51 (73.9%) | 43 (57.3%) | 40 (69.0%) | |
| Female | 68 (33.7%) | 18 (26.1%) | 32 (42.7%) | 18 (31.0%) | |
| cT stage | |||||
| T1 | 32 (15.8%) | 8 (11.6%) | 12 (16.0%) | 12 (20.7%) | |
| T2 | 53 (26.2%) | 12 (17.4%) | 23 (30.7%) | 18 (31.0%) | |
| T3 | 38 (18.8%) | 9 (13.0%) | 15 (20.0%) | 14 (24.1%) | |
| T4 | 79 (39.2%) | 40 (58.0%) | 25 (33.3%) | 14 (24.1%) | |
| pN stage | 0.130 | ||||
| N0 | 120 (59.4%) | 36 (52.2%) | 44 (58.7%) | 40 (69.0%) | |
| N1 | 30 (14.9%) | 9 (13.0%) | 15 (20.0%) | 6 (10.3%) | |
| N2 | 52 (25.7%) | 24 (34.8%) | 16 (21.3%) | 12 (20.7%) | |
| N3 | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | |
| Site | 0.112 | ||||
| Oral cavity | 191 (94.6%) | 62 (89.9%) | 72 (96.0%) | 57 (98.3%) | |
| Oropharynx | 11 (5.4%) | 7 (10.1%) | 3 (4.0%) | 1 (1.7%) | |
| Smoking history | |||||
| Smoker | 93 (46.0%) | 39 (56.5%) | 25 (33.3%) | 29 (50.0%) | |
| Nonsmoker | 104 (51.5%) | 28 (40.6%) | 48 (64.0%) | 28 (48.3%) | |
| Missing | 5 (2.5%) | 2 (2.9%) | 2 (2.7%) | 1 (1.7%) | |
| Alcohol history | |||||
| Drinker | 58 (28.7%) | 26 (37.7%) | 13 (17.3%) | 19 (32.8%) | |
| Nondrinker | 139 (68.8%) | 41 (59.4%) | 60 (80.0%) | 38 (65.5%) | |
| Missing | 5 (2.5%) | 2 (2.9%) | 2 (2.7%) | 1 (1.7%) | |
| Perineural invasion | 0.150 | ||||
| Absence | 146 (72.3%) | 47 (68.1%) | 50 (66.7%) | 49 (84.5%) | |
| Presence | 23 (11.4%) | 10 (14.5%) | 9 (12.0%) | 4 (6.9%) | |
| Missing | 33 (16.3%) | 12 (17.4%) | 16 (21.3%) | 5 (8.6%) | |
| Vascular emboli | 0.286 | ||||
| Absence | 164 (81.2%) | 55 (79.7%) | 58 (77.3%) | 51 (87.9%) | |
| Presence | 5 (2.5%) | 2 (2.9%) | 1 (1.3%) | 2 (3.4%) | |
| Missing | 33 (16.3%) | 12 (17.4%) | 16 (21.3%) | 5 (8.6%) | |
| Diffuse infiltration | 0.261 | ||||
| Absence | 137 (67.8%) | 48 (69.6%) | 45 (60.0%) | 44 (75.9%) | |
| Presence | 32 (15.8%) | 9 (13.0%) | 14 (18.7%) | 9 (15.5%) | |
| Missing | 33 (16.3%) | 12 (17.4%) | 16 (21.3%) | 5 (8.6%) | |
| Microscopic ECS | |||||
| Absence | 160 (79.2%) | 50 (72.5%) | 57 (76.0%) | 53 (91.4%) | |
| Presence | 9 (4.5%) | 7 (10.1%) | 2 (2.7%) | 0 (0.0%) | |
| Missing | 33 (16.3%) | 12 (17.4%) | 16 (21.3%) | 5 (8.6%) | |
| Adjuvant radiotherapy | |||||
| Yes | 142 (70.3%) | 56 (81.2%) | 53 (70.7%) | 55 (68.8%) | |
| No | 60 (29.7%) | 13 (18.8%) | 22 (29.3%) | 25 (31.2%) | |
| p16 status* | 0.406 | ||||
| p16+ | 2 (18.2%) | 1 (14.3%) | 1 (33.3%) | 0 (0.0%) | |
| p16− | 8 (72.7%) | 6 (85.7%) | 1 (33.3%) | 1 (100.0%) | |
| Missing | 1 (9.1%) | 0 (0.0%) | 1 (33.3%) | (0.0%) |
Note: * p16 status was evaluated only in patients with oropharyngeal squamous cell carcinoma.
Figure 2Kaplan–Meier survival curve for TIL level and DFS time according to different TIL levels.
Figure 3Kaplan–Meier survival curve for TIL level and DSS time according to different TIL levels.
Figure 4Kaplan–Meier survival curve for types of tumor stroma and DFS time according to different types of tumor stroma.
Figure 5Kaplan–Meier survival curve for types of tumor stroma and DSS time according to different types of tumor stroma.
Univariate Analysis and Multivariate Analysis for the Estimation of Risk Factors for the DFS and DSS in Patients with HNSCC
| Variable | Hazard Ratio | 95% Confidence Interval | |
|---|---|---|---|
| Univariate analysis for DFS | |||
| TIL level (high, moderate, low) | 0.730 | 0.578-0.924 | |
| Type of tumor stromal area (cell-rich, middle, stroma-rich) | 1.062 | 0.869-1.299 | 0.555 |
| T stage (T1, T2, T3, T4) | 1.055 | 0.888-1.255 | 0.542 |
| pN status (N0, N1, N2, N3) | 1.418 | 1.149-1.750 | |
| Site (Oral versus Oropharynx) | 2.642 | 1.324-5.273 | |
| Age (≤60 versus >60) | 1.030 | 0.706-1.504 | 0.877 |
| Sex (male versus female) | 0.873 | 0.577-1.320 | 0.519 |
| Tobacco use (absence versus presence) | 1.057 | 0.750-1.489 | 0.753 |
| Alcohol use (absence versus presence) | 1.050 | 0.725-1.520 | 0.796 |
| Radiotherapy (Yes versus No) | 1.072 | 0.720-1.597 | 0.731 |
| Multivariate analysis for DFS | |||
| TIL level (high, moderate, low) | 0.786 | 0.618-0.999 | |
| pN status (N0, N1, N2, N3) | 1.351 | 1.091-1.673 | |
| Site (oral versus oropharynx) | 1.935 | 0.947-3.952 | 0.070 |
| Univariate analysis for DSS | |||
| TIL level (High, moderate, low) | 0.758 | 0.590-0.974 | |
| Type of tumor stromal area (cell-rich, middle, stroma-rich) | 1.089 | 0.878-1.350 | 0.439 |
| T stage (T1, T2, T3, T4) | 1.225 | 1.015-1.480 | |
| pN status (N0, N1, N2, N3) | 1.692 | 1.351-2.118 | |
| Site (oral versus oropharynx) | 3.173 | 1.583-6.359 | |
| Age (≤60 versus >60) | 0.919 | 0.613-1.380 | 0.685 |
| Sex (male versus female) | 0.615 | 0.386-0.980 | |
| Tobacco use (absence versus presence) | 1.220 | 0.836-1.780 | 0.303 |
| Alcohol use (absence versus presence) | 1.438 | 0.964-2.147 | 0.075 |
| Radiotherapy (Yes versus No) | 1.073 | 0.701-1.643 | 0.744 |
| Multivariate analysis for DSS (forward method) | |||
| Site (oral versus oropharynx) | 2.253 | 1.093-4.642 | |
| pN status (N0, N1, N2, N3) | 1.600 | 1.250-2.049 | |
| TILs level (high, moderate, low) | 0.843 | 0.647-1.098 | 0.206 |
| T stage (T1, T2, T3, T4) | 0.991 | 0.800-1.228 | 0.934 |
| Sex (male versus female) | 0.703 | 0.438-1.129 | 0.145 |
*Note: DFS, disease-free survival; DSS, disease-specific survival; TILs: Tumor infiltrating lymphocyte.